New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
07:09 EDTSLXPSalix risk/reward favorable ahead of trial, says Stifel
Stifel is comfortable owning Salix ahead of the expected release of TARGET-3 retreatment data for Xifaxan in diarrhea-related IBS in coming weeks. The firm thinks the stock could rise significantly if the data is positive, while a decline in shares on negative results would create a buying opportunity. The firm thinks there is a 65%-70% chance that the data will be positive, and it estimates that the stock could climb up to 20%-25% on positive data. It keeps a Buy rating on the stock.
News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
17:32 EDTSLXPSalix announces tentative FDA approval of UCERIS rectal foam
Subscribe for More Information
15:55 EDTSLXPSalix price target raised to $172 from $163 at Buckingham
Subscribe for More Information
15:41 EDTSLXPSalix calls active on takeover chatter
Subscribe for More Information
07:47 EDTSLXPFDA PDUFA Date for Salix Pharmaceuticals Budesonide is September 15, 2014
September 12, 2014
10:00 EDTSLXPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:06 EDTSLXPFollow-up: Salix initiated with an Underperform at Credit Suisse
Subscribe for More Information
06:41 EDTSLXPSalix initiated with an Underperform at Credit Suisse
Subscribe for More Information
September 8, 2014
07:21 EDTSLXPJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use